Skip to main content

Table 1 Baseline characteristics of the participants1

From: Effects of vitamin K2 supplementation on atherogenic status of individuals with type 2 diabetes: a randomized controlled trial

Variables

Vitamin K2 group

Placebo group

P-value2

Number

32

31

Age, years

56.8 ± 7.34

58.2 ± 7.39

0.440

Disease duration, years

7.81 ± 4.27

9.68 ± 5.93

0.156

Female, n (%)

21 (65.6%)

18 (58.1%)

0.609

Smokers, n (%)

5 (15.6%)

2 (6.5%)

0.426

Academic education, n (%)

7 (21.9%)

14 (45.1%)

0.201

Weight, kg

7.29 ± 14.7

74.9 ± 16.7

0.607

Body mass index, kg/m2

27.9 ± 4.90

27.5 ± 3.60

0.729

Physical activity, Met-min/week

425 (209–679)

834 (240–1386)

0.063

Atherogenicity index

Castelli index Ӏ

3.33 ± 0.79

3.65 ± 0.89

0.133

Triglycerides / HDL-C ratio

1.33 ± 0.85

1.64 ± 1.06

0.194

AC3

−0.17 ± 0.48

0.01 ± 0.44

0.124

Castelli index ӀӀ

1.68 ± 0.48

1.80 ± 0.51

0.308

TyG-Index

9.02 ± 0.56

9.23 ± 0.64

0.172

AIP

0.40 ± 0.27

0.51 ± 0.24

0.109

METS-IR

43.9 ± 9.09

45.1 ± 7.14

0.576

LCI3

1.95 ± 0.37

2.03 ± 0.40

0.382

  1. AC Atherogenic Coefficient, AIP Atherogenic Index of Plasma, LCI Lipoprotein Combine Index, METS-IR Metabolic Score for Insulin Resistance, TyG-Index Triglyceride glucose Index
  2. 1Data are presented as mean ± SD, median (quartile 1-quartile 3), and number (%)
  3. 2Based on T-test for normally-distributed, Mann-Whitney U-test for non-normally distributed and chi-square for categorical variables
  4. 3Natural log-transformed values are reported